Distinct gene signature revealed in white blood cells, CD4 and CD8 T cells in (NZBx NZW) F1 lupus mice after tolerization with anti-DNA Ig peptide

Genes and Immunity

Volumn 11, Issue 4, 2010, Pages 294-309

  Singh, R P ^a   Dinesh, R ^a   Elashoff, D ^a   De Vos, S ^a   Rooney, R J ^b   Patel, D ^b   La Cava, A ^a   Hahn, B H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Genome Explorations Inc   (United States)

Author keywords

Autoimmunity; Gene expression; Systemic lupus erythematosus; T cells; Tolerance suppression

Indexed keywords

ALPHA INTERFERON RECEPTOR; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; DNA ANTIBODY; GENE PRODUCT; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; PROTEIN IFI202B; PROTEIN IFNAR1; PROTEIN TRP 53; SMAD PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONSENSUS SEQUENCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC PREDISPOSITION; GENETIC SELECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LEUKOCYTE DIFFERENTIAL COUNT; LUPUS LIKE SYNDROME; MICROARRAY ANALYSIS; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA; FEMALE; GENE EXPRESSION PROFILING; IMMUNOGLOBULINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; POLYMERASE CHAIN REACTION; UP-REGULATION;

MURINAE; MUS;

EID: 77953121527     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2010.6     Document Type: Article

References (70)

1. Linker-Israeli M, Quismorio Jr FP, Horwitz DA. CD 8 lymphocytes from patients with systemic lupus erythemato-sus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990; 33: 1216-1225.
2. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85: 303-306.
3. Hahn BH. Lessons in lupus: the mighty mouse. Lupus 2001; 10: 589-593.
4. Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Ghio M et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 2001; 166: 6452-6457.
5. Karpouzas GA, La Cava A, Ebling FM, Singh RR, Hahn BH. Differences between CD8+ T cells in lupus-prone (NZB x NZW) F1 mice and healthy (BALB/c x NZW) F1 mice may influence autoimmunity in the lupus model. Eur J Immunol 2004; 34: 2489-2499.
6. La Cava A, Ebling FM, Hahn BH. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol 2004; 173: 3542-3548.
7. Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGF(3-secreting CD8+ T cell suppressors. J Immunol 2005; 175: 7728-7737.
8. Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321-1324.
9. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-1175.
10. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000; 6: 1176-1182.
11. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR et al. Beta-cell function in new-onset type 1 diabetes and immuno-modulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358: 1749-1753.
12. Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA 2004; 101: 4228-4233.
13. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562.
14. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD 4+CD25 regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005; 102: 6449-6454.
15. Sharabi A, Haviv A, Zinger H, Dayan M, Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin Immunol 2006; 119: 146-155.
16. Hahn BH, Anderson M, Le E, La Cava A. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum 2008; 58: 2488-2497.
17. Kaliyaperumal A, Michaels MA, Datta SK. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 1999; 162: 5775-5783.
18. Eilat E, Dayan M, Zinger H, Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci USA 2001; 98: 1148-1153.
19. Riemekasten G, Riemekasten G, Langnickel D, Enghard P, Undeutsch R, Humrich J et al. Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 2004; 173: 5835-5842.
20. Kang HK, Michaels MA, Berner BR, Datta SK. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005; 174: 3247-3255.
21. Hahn BH, Hahn BH, Ebling F, Singh RR, Singh RP, Karpouzas G et al. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 2005; 1051: 433-441.
22. Sharabi A, Sharabi A, Luger D, Ben-David H, Dayan M, Zinger H et al. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol 2007; 179: 4979-4987.
23. Kang SM, Tang Q, Bluestone JA. CD4(+)CD25(+) regulatory T Cells in transplantation: progress, challenges and prospects. Am J Transplant 2007; 7: 1457-1463.
24. Singh RP, La Cava A, Wong M, Ebling F, Hahn BH. CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 2007; 178: 7649-7657.
25. Singh RP, La Cava A, Hahn BH. pConsensus peptide induces tolerogenic CD8+ Tcells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol 2008; 180: 2069-2080.
26. Hahn BH, Hahn BH, Singh RR, Wong WK, Tsao BP, Bulpitt K et al. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001; 44: 432-441.
27. Singh RR, Singh RR, Ebling FM, Albuquerque DA, Saxena V, Kumar Vet al. Induction of autoantibody production is limited in nonautoimmune mice. J Immunol 2002; 169: 587-594.
28. Nakamura K, Kitani A. Strober WCell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194: 629-644.
29. Nakamura K, Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004; 172: 834-842.
30. McHugh RS, McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16: 311-323.
31. Shevach EM. CD4+ CD25+ suppressor Tcells: more questions than answers. Nat Rev Immunol 2002; 2: 389-400.
32. Rus V, Rus V, Atamas SP, Shustova V, Luzina IG, Selaru F et al. Expression of cytokine-and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol 2002; 102: 283-290.
33. Maas K, Maas K, Chan S, Parker J, Slater A, Moore J et al. Cutting edge: molecular portrait of human autoimmune disease. J Immunol 2002; 169: 5-9.
34. Deng YJ, Deng YJ, Huang ZX, Zhou CJ, Wang JW, You Yet al. Gene profiling involved in immature CD4+ T lymphocyte responsible for systemic lupus erythematosus. Mol Immunol 2006; 43: 1497-1507.
35. Xu L, Zhang L, Yi Y, Kang HK, Datta SK. Human lupus Tcells resist inactivation and escape death by upregulating COX-2. Nat Med 2004; 10: 411-415.
36. Qing X, Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Auto-immun Rev 2004; 3: 505-509.
37. Baechler EC, Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
38. Bennett L, Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
39. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383-392.
40. Feng X, Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2951-2962.
41. Geiben-Lynn R, Geiben-Lynn R, Kursar M, Brown NV, Addo MM, Shau H et al. HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family. J Biol Chem 2003; 278: 1569-1574.
42. Moon EY, Moon EY, Noh YW, Han YH, Kim SU, Kim JM et al. T lymphocytes and dendritic cells are activated by the deletion of peroxiredoxin II (Prx II) gene. Immunol Lett 2006; 102: 184-190.
43. Han YH, Han YH, Kim HS, Kim JM, Kim SK, Yu DY et al. Inhibitory role of peroxiredoxin II (Prx II) on cellular senescence. FEBS Lett 2005; 579: 4897-4902.
44. Zhang P, Zhang P, Liu B, Kang SW, Seo MS, Rhee SG et al. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem 1997; 272: 30615-30618.
45. Chikamori K, Chikamori K, Hill JE, Grabowski DR, Zarkhin E, Grozav AG et al. Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest. Leukemia 2006; 20: 1809-1818.
46. Punt JA, Osborne BA, Takahama Y, Sharrow SO, Singer A. Negative selection of CD4+CD8+ thymocytes by T cell receptor-induced apoptosis requires a costimulatory signal that can be provided by CD28. J Exp Med 1994; 179: 709-713.
47. Yu XZ, Martin PJ, Anasetti C. CD28 signal enhances apoptosis of CD8 T cells after strong TCR ligation. J Immunol 2003; 170: 3002-3006.
48. Radvanyi LG, Radvanyi LG, Shi Y, Vaziri H, Sharma A, Dhala R et al. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 1996; 156: 1788-1798.
49. Daniel PT, Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T et al. Costimulatory signals through B7 1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 1997; 159: 3808-3815.
50. Kerstan A, Armbruster N, Leverkus M, Hunig T. Cyclosporin A abolishes CD28-mediated resistance to CD95-induced apoptosis via superinduction of caspase-3. J Immunol 2006; 177: 7689-7697.
51. Spaulding C, Guo W, Effros RB. Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol 1999; 34: 633-644.
52. Valenzuela HF, Effros RB. Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol 2002; 105: 117-125.
53. Effros RB, Dagarag M, Spaulding C, Man J. The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev 2005; 205: 147-157.
54. Colovai AI, Colovai AI, Mirza M, Vlad G, Wang S, Ho E et al. Regulatory CD8+CD28-T cells in heart transplant recipients. Hum Immunol 2003; 64: 31-37.
55. Saurwein-Teissl M, Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(\) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002; 168: 5893-5899.
56. Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8(+)CD28(\) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 2003; 52: 599-607.
57. Filaci G, Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G et al. CD8+ CD28-T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179: 4323-4334.
58. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003; 40: 643-672.
59. Morigi M, Morigi M, Macconi D, Riccardi E, Boccardo P, Zilio P et al. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice. J Pharmacol Exp Ther 1991; 258: 601-606.
60. Palacios I, Palacios I, Miguélez R, Sánchez-Pernaute O, Gutierrez S, Egido J et al. A platelet-activating factor receptor antagonist prevents the development of chronic arthritis in mice. J Rheumatol 1999; 26: 1080-1086.
61. Hilliquin P, Guinot P, Chermat-Izard V, Puechal X, Menkes CJ. Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol 1995; 22: 1651-1654.
62. Aldemir H, Aldemir H, Prod'homme V, Dumaurier MJ, Retiere C, Poupon G et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005; 175: 7791-7795.
63. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL et al. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005; 175: 7796-7799.
64. Elmann A, Elmann A, Sharabi A, Dayan M, Zinger H, Ophir R et al. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum 2007; 56: 2371-2381.
65. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-b to convert naive CD4+CD25-cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007; 178: 2018-2027.
66. Zheng SG, Wang J, Horwitz DA. Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 2008; 180: 7112-7116.
67. Butz NV, Gronostajski RM, Campbell CE. T-box proteins differentially activate the expression of the endogenous interferon gamma gene versus transfected reporter genes in non-immune cells. Gene 2006; 377: 130-139.
68. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005; 307: 430-433.
69. Eilat E, Zinger H, Nyska A, Mozes E. Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1-and CDR3-based peptides of a pathogenic autoantibody. J Clin Immunol 2000; 20: 268-278.
70. Tsao BP, Tsao BP, Ebling FM, Roman C, Panosian-Sahakian N, Calame K et al. Structural characteristics of the variable regions of immunoglobulin genes encoding a pathogenic autoantibody in murine lupus. J Clin Invest 1990; 85: 530-540.